We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

53 hedge funds and large institutions have $121M invested in Clearside Biomedical in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 10

27% more capital invested

Capital invested by funds: $95.2M → $121M (+$25.8M)

0.34% more ownership

Funds ownership: 3.16% → 3.5% (+0.34%)

10% less funds holding

Funds holding: 59 → 53 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
53
Holders Change
-6
Holders Change %
-10.17%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
28
Reduced
10
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$5.73M
2
BlackRock
BlackRock
New York
+$4M
3
State Street
State Street
Massachusetts
+$1.04M
4
Northern Trust
Northern Trust
Illinois
+$863K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$738K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.38M
2
ACP
Acuta Capital Partners
California
-$1.39M
3
NC
Nexthera Capital
New York
-$959K
4
PA
Perceptive Advisors
New York
-$736K
5
PP
PDT Partners
New York
-$534K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$2K -$14.8K -123 -89%
Barclays
52
Barclays
United Kingdom
$1K -$1.8K -15 -58%
O
53
OrbiMed
New York
– -$2.38M -20,000 Closed
ACP
54
Acuta Capital Partners
California
– -$1.39M -11,667 Closed
NC
55
Nexthera Capital
New York
– -$959K -8,051 Closed
PP
56
PDT Partners
New York
– -$534K -4,487 Closed
Swiss National Bank
57
Swiss National Bank
Switzerland
– -$224K -1,880 Closed
AA
58
ALPS Advisors
Colorado
– -$168K -1,408 Closed
Millennium Management
59
Millennium Management
New York
– -$163K -1,365 Closed
AFP
60
Ausdal Financial Partners
Iowa
– -$94K -787 Closed
SF
61
Synovus Financial
Georgia
– -$28K -233 Closed
SO
62
STRS Ohio
Ohio
– -$20K -173 Closed
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
– -$12.8K -107 -99%
Canada Life
64
Canada Life
Manitoba, Canada
– -$8K -67 Closed
FDCDDQ
65
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$1.19K -10 Closed
MAM
66
Meeder Asset Management
Ohio
– -$1K -9 Closed
1 2
3

CLSD Hedge Fund Activity: Q2 2017 in Review

53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2017, worth a combined $121M — up 27% from $95.2M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CLSD and 7 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 28 added.

The largest buyer was Wellington Management Group, adding an estimated $5.73M. The largest seller was OrbiMed, exiting entirely with an estimated $2.38M sold.

  • 53 institutional investors held Clearside Biomedical (CLSD) as of Q2 2017, down from 59 in Q1 2017.
  • Funds reported $121M of Clearside Biomedical stock for Q2 2017, up 27% quarter-over-quarter.
  • 7 funds opened new Clearside Biomedical positions in Q2 2017 and 13 closed out, a net change of -6 holders.
  • The largest Clearside Biomedical buyer in Q2 2017 was Wellington Management Group, an estimated $5.73M added.
  • The largest Clearside Biomedical seller in Q2 2017 was OrbiMed, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2017.